Candel Therapeutics Future Growth
Future criteria checks 2/6
Candel Therapeutics is forecast to grow earnings and revenue by 138.9% and 256.9% per annum respectively while EPS is expected to grow by 135% per annum.
Key information
138.9%
Earnings growth rate
135.0%
EPS growth rate
| Biotechs earnings growth | 28.5% |
| Revenue growth rate | 256.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
Jul 01Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Apr 15Candel gets European orphan drug designation for brain, spinal cord tumor treatment
Sep 15Candel Therapeutics appoints CFO, chief medical officer
Sep 07Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Oct 21Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 75 | 9 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -51 | N/A | N/A | 1 |
| 9/30/2024 | N/A | -52 | -29 | -29 | N/A |
| 6/30/2024 | N/A | -50 | -31 | -31 | N/A |
| 3/31/2024 | N/A | -37 | -32 | -32 | N/A |
| 12/31/2023 | N/A | -38 | -35 | -34 | N/A |
| 9/30/2023 | 0 | -32 | -34 | -34 | N/A |
| 6/30/2023 | 0 | -32 | -35 | -34 | N/A |
| 3/31/2023 | 0 | -27 | -35 | -34 | N/A |
| 12/31/2022 | 0 | -19 | -33 | -31 | N/A |
| 9/30/2022 | 0 | -12 | -31 | -30 | N/A |
| 6/30/2022 | 0 | -20 | -29 | -27 | N/A |
| 3/31/2022 | 0 | -33 | -26 | -25 | N/A |
| 12/31/2021 | 0 | -36 | -24 | -22 | N/A |
| 9/30/2021 | 0 | -48 | -22 | -20 | N/A |
| 6/30/2021 | 0 | -35 | -17 | -15 | N/A |
| 3/31/2021 | 0 | -20 | -14 | -12 | N/A |
| 12/31/2020 | 0 | -18 | -11 | -9 | N/A |
| 12/31/2019 | 0 | -8 | -5 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CADL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CADL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CADL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CADL's revenue (256.9% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: CADL's revenue (256.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CADL's Return on Equity is forecast to be high in 3 years time